09 March 2021
Visiongain has published a new Lead Series report on Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031. The global ophthalmic drugs manufacturers market is estimated to be valued at US$29.8 billion in 2021 and is projected to reach at a market value of US$xx billion by 2031.
Curious to know how hard the COVID-19 has Impacted the Competitor’s Revenue?
Buy this report to discover the impact of COVID-19 and the subsequent recession/ economic recovery on the ophthalmic drugs manufacturers. Establish which of the new mergers, acquisitions and collaborations are changing competitive dynamics today.
Are you in the global race? Where do you stand in the cut throat global competition?
The global market for ophthalmic drugs is increasing yearly. Your competitors in the ophthalmic drugs market are benefiting from key opportunities – what are they and how can you benefit? This report will tell you.
With product approvals over the next decade set to be a key issue facing all competitors in the market – you must discover the essential strategies being implemented by key market players between 2015 and Jan 2021.
By ordering and reading our brand-new report today you stay better informed and ready to act. Visiongain’s study is intended for anyone requiring commercial analyses for the top 50 ophthalmic drugs manufacturers market. You find data, trends and predictions.
Top 50 Companies Profiled in the Report
Top 20 Big Ophthalmic Drugs Manufacturing Company Profiles
• Johnson & Johnson Vision Company
• Roche Holding AG (Roche)
• Novartis AG
• Merck & Co.
• AbbVie Inc
• Essilor International S.A.
• Teva Pharmaceuticals
• Otsuka Pharmaceutical
• Bausch Health
• Alcon Inc.
• Regeneron Pharmaceuticals Inc.
• Edwards Lifesciences Corp
• Coopervision Company
• Santen Pharmaceuticals
• Rohto Pharmaceutical Co., Ltd.
• Carl Zeiss Meditec AG
Top 20 Mid-Range Ophthalmic Drugs Manufacturing Company Profiles
• Topcon Corporation
• Veeva System Inc
• Recipharm AB
• Menicon co ltd.
• Chengdu Kanghong Pharmaceutical
• Glaukos Corporation
• Staar Surgicals
• Aerie Pharmaceuticals
• Hoya Corporation
• Alimera Sciences
• Bora Pharmaceuticals Co Ltd
• EyeGate Pharmaceuticals
• Kalvista Pharmaceuticals Inc
• Ellex Medical Lasers Ltd.
• Thrombo Genics NV
• EyeGate Pharmaceuticals
• OphthaliX /Wize Pharma
Top 10 Ophthalmic Drugs Manufacturing Companies to Watch
• Gensight Biologics
• Phio Pharmaceuticals Corp
• Kubota Pharmaceutical Holdings Co Ltd
• Aerpio Therapeutics
• Ampio Pharmaceuticals
• Kodiak Sciences Inc
• Opsis Therapeutics
• Grevis Pharmaceutical
• The Innovexia Life Sciences
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.